Dr Nurbhai has more than 25 years of experience in the strategic and operational leadership of all phases of clinical research and development at companies across Europe and the US
Mission Therapeutics has appointed Dr Suhail Nurbhai as Chief Medical Officer (CMO) with immediate effect.
He joins Mission from VHsquared, where he held the position of CMO since 2014.
Prior to VHsquared, Suhail was Senior Vice President and Head of Development and Medical Affairs for Shionogi in Europe. He joined Shionogi from Takeda where he was Vice President and Head of Clinical and Analytical Science in Europe, with responsibility for all clinical science activities.
Suhail’s initial industry experience was at Pfizer, where he spent 12 years, initially in Sandwich, UK and then at global R&D Headquarters in Connecticut, USA. During his time at Pfizer he held roles across multiple therapeutic areas including GI/GU, anti-bacterial, sexual medicine and anti-fungal, prior to completing his time at Pfizer as Head of Neuroscience Clinical R&D at the Groton site in Connecticut.
During his career he has led teams bringing multiple compounds from pre-clinical phase into clinical studies in both Europe and US and achieved multiple NDA and MAA submissions and approvals.
Suhail qualified in Medicine at Dundee University in Scotland and completed his post-graduate medical training at Hope Hospital in the University of Manchester.
Commenting on the appointment, Dr Anker Lundemose, CEO of Mission Therapeutics said: “We are pleased to be welcoming Suhail to further strengthen Mission’s leadership team. His in-depth knowledge and proven track record in clinical research will be invaluable as we work to bring our first-in-class USP30 inhibitor compound into the clinic. Suhail’s appointment is the last of a series of organisational changes, including the promotions of Dr Paul Thompson and Dr Nick Edmunds, to ready the Company for this next phase.”
Dr Suhail Nurbhai added: “It’s great to be joining Mission at such an exciting time for the company. The ongoing collaboration with AbbVie and recently signed agreement with Pfizer represent solid industry validation of the Company’s approach and ground-breaking technology. I look forward to building on this success progressing its lead assets into the clinic.”